What the top R and D managers from 4 big Pharma companies were talking about, yes they have a bit more of a cushion than Wall Street, but the failure rates and dollars invested don’t seem to be coming together too well either, from the Wall Street Health Blog. When you add it up, just these 4 were...
He also did recognize the effect of current budget cuts are having on the progression of R and D, as anyone who applies for and receives grants these days knows the bar has been raised and it is a bit more difficult to secure them, as a result many are looking to investors outside the NIH for funding...
Posted to
The Medical Quack .... by Barbara Duck
on 09-24-2008
Filed under: Medically Related, Pharma/FDA News, Other Items of Interest, Genomics, healthcare, Biotech, Grants, Budgets, R and D, NIH, National Institue of Health
Many of the generic manufacturers started years back with knock off drugs to sell locally in India, but now the game is changing to where US Pharma is using some of the talent, which costs less than R and D individuals here in the states, to further develop existing work, in other words somewhat continue...
Posted to
The Medical Quack .... by Barbara Duck
on 09-05-2008
Filed under: Medically Related, Pharma/FDA News, Genomics, drugs, Pharma, Biotech, Cancer, FDA, Budgets, R and D, Alzheimers, Outsourcing
By comparison, small bonuses were paid to scientists and doctors. $35 million in bonuses all together were handed out. The head of the criminal investigation division made more than the director of the FBI and the person in charge of revising the bonus system, well, they got the biggest bonus...
The basis of the current affairs of the FDA are not unlike many other stories being told today. We live in a world of transparency, and we are all still getting used to it for that matter, but things don’t fit under the carpet anymore. The old saying of “if it isn’t broke, don’t fix it”...